Journal of Clinical Oncology
Articles in this Issue
Huntington’s disease as a protective factor for non-melanoma skin cancer: A retrospective cohort study using the TriNetX dataset.
e21585 Background: Huntington’s disease (HD) is an inherited neurodegenerative disorder caused by a mutation in the encoded protein huntingtin (HTT)....
Comparative analysis of deep learning model artificial intelligence and radiologists in breast tumor classification: A study in Uzbekistan.
e13650 Background: To evaluate and compare the diagnostic performance of a deep learning-based artificial intelligence (AI) system versus three radiologis...
Patterns of immunotherapy use in dMMR/MSI-H metastatic CRC.
3557 Background: Immune checkpoint inhibitors (ICI) are more effective in mismatch repair deficient/microsatellite instability high (dMMR/MSI-H) metastati...
Training an alternate oncology workforce: Attendee feedback.
e13521 Background: Access to cancer care remains a significant challenge. The lack of skilled personnel is a major hindrance. An innovative district cance...
Phase 1 study of TT-00973-MS, a highly selective and potent AXL inhibitor, in patients with advanced solid tumors.
3106 Background: AXL is a member of the TAM family activated by the high-affinity ligand Gas6. The Gas6/AXL signaling pathway plays a critical role in dru...
A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge).
TPS5119 Background: Prostate cancer relies on the androgen receptor (AR) pathway as a key oncogenic driver. BMS-986365 is a heterobifunctional, orally bio...
Mathematical modeling applied to the growth and invasion of gliomas: A narrative review of methods and applications.
e13591 Background: The study of glioma growth (gg) and invasion has greatly benefited from the application of mathematical models (MM) , which provide ins...
Krascendo 2: A phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, <i>KRAS</i> G12C-mutated non-small cell lung cancer (NSCLC).
TPS8656 Background: KRAS G12C mutations are found in ~12% of NSCLC cases. The reco...
Influence of race, ethnicity, and nativity on distribution and outcomes among women with choriocarcinoma.
e17653 Background: Gestational trophoblastic neoplasia (GTN) is a rare group of malignancies in which abnormal trophoblastic (placental) cells proliferate...
Recurrence patterns in the prospective, randomized, controlled, multicenter phase III ESOPEC trial comparing perioperative chemotherapy with preoperative chemoradiotherapy in patients with esophageal adenocarcinoma.
4014 Background: The ESOPEC trial (NCT02509286) showed that perioperative chemotherapy improved overall and progression free survival in pts with esophage...
Retifanlimab with bevacizumab and hypofractionated radiotherapy to treat recurrent glioblastoma.
TPS2092 Background: Glioblastoma (GBM) is the most common primary brain malignancy in adults. GBM is universally recurrent and associated with dismal outc...
NCI 10479: A phase I dose escalation-expansion trial of sunitinib malate plus lutetium (Lu-177) dotatate in somatostatin receptor positive pancreatic neuroendocrine tumors.
TPS4226 Background: Patients with metastatic or unresectable pancreatic neuroendocrine tumors (PanNETs) have a poor prognosis, even with currently availab...
Association of tumor-informed ctDNA-based molecular residual disease (MRD) with clinical outcomes for upper tract urothelial cancer (UTUC).
4565 Background: Upper tract urothelial carcinoma (UTUC) accounts for 5–10% of all urothelial carcinomas. Given its aggres...
JAK inhibitor for the treatment of steroid refractory and life-threatening immune-related adverse events secondary to immune checkpoint inhibitors.
2643 Background: Immune checkpoint inhibitors (ICIs) boost anti-tumor immune responses but carry the risk of off-target effects, manifesting as immune-rel...
Baseline LDH as a prognostic biomarker of early treatment failure in lung cancer.
e20023 Background: Despite advances in lung treatment modalities, outcomes still vary greatly and predicting treatment failure remains challenging. This h...
Mortality trends in multiple myeloma and cardiovascular disease in the US (1999–2020).
e23056 Background: Multiple Myeloma (MM) and cardiovascular disease (CVD) significantly contribute to mortality in the U.S. This study examines mortality...
Determining primary or delayed surgery approach in fibrolamellar carcinoma of the liver based on stage.
e16269 Background: Fibrolamellar carcinoma (FLC) is a rare, primary liver cancer usually presenting as advanced stage. FLC is often described as a "surgic...
Characteristics, treatment patterns, and outcomes of HIV-associated lung cancer.
8050 Background: Lung cancer is a leading cause of cancer-related mortality in people with HIV (PWH). Prior studies have shown worse survival in PWH with...
Clinicodemographic predictors of enrollment and outcomes in early phase oncology clinical trials in a diverse urban population.
e13514 Background: Early phase clinical trials (EPCTs) evaluate the safety, toxicity, pharmacokinetics, and preliminary efficacy of novel anticancer agent...
Safety of DOACs in Budd-Chiari syndrome: A real-world comparison from the TriNetX Global Collaborative Network.
e23289 Background: Anticoagulation is the cornerstone treatment for all types of Budd-Chiari Syndrome (BCS), often requiring lifelong therapy. While hepar...
Efficacy of immunochemotherapy (ICT) in patients (pts) with metastatic gastric cancer (mGC) in context of ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) and PD-L1 expression: Results of the meta-analysis.
e16062 Background: Addition of anti-PD1 antibodies to chemotherapy (CT) in pts with mGC has become a standard of care. However, there is no consensus on t...
Prospective monitoring of prostate specific membrane antigen–positive biochemically recurrent prostate cancer (PSMA+ BCR): Preliminary data from 6-month PSMA follow-up.
5098 Background: PSMA imaging can identify recurrent prostate cancer after definitive surgery/radiation prior to detection on computed tomography (CT) or...
A phase 2 study of HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy as first-line therapy in advanced squamous non-small cell lung cancer.
8561 Background: Approved first-line therapies of PD-L1/PD-1 inhibitors plus chemotherapy conferred significant survival benefits for advanced squamous no...
Effect of race/ethnicity on clinical outcomes for metastatic colorectal cancer (mCRC) patients in phase 1 trials: A dual institution experience.
3575 Background: Patients with mCRC who progress on standard of care therapies have limited therapeutic options and are associated with poor prognoses. Ph...
Development and validation of a prognostic risk score for hepatocellular carcinoma recurrence post–liver transplant: Insights from the UNOS database.
4125 Background: For over two decades, the criteria for liver transplantation (LT) in hepatocellular carcinoma (HCC) have been well-established, yet recur...